Synthesis of 99mTc-p-SCN-Bzl-TCMC-bevacizumab for vascular endothelial growth factor (VEGF) receptor imaging using ovarian cancer model

In this study bevacizumab was labeled with 99mTc using p-SCN-Bzl-TCMC as a chelator for non invasive imaging of VEGF receptor in ovarian tumor Sprague Dawley rat and New Zealand rabbit models. High radiochemical purity and stability were observed using 0.4 mL of conjugated TCMC-bevacizumab. In vitro binding studies showed higher uptake of labeled conjugated bevacizumab with high metastatic SKOV-3 ipl cells as compared to poor metastatic SKOV-3. Biodistribution in rat model confirmed higher accumulation of labeled conjugated bevacizumab in the site infected with SKOV-3 ipl cells as compared to SKOV-3. Images of ovarian tumor rabbit model validated its specificity and efficacy as a promising ovarian tumor imaging agent.